CA
NZ
UK
AU
IND
US
Protagenic Therapeutics, Inc. (OTC: PTIX) announced it plans to submit an Investigational New Drug (IND) application for PT00114 by the end of 2026. The positive feedback from the FDA signals a critical step forward for the company in bringing this investigational therapy to market.
This surge represents a substantial improvement over the $56,325 recorded in the first quarter of the same year. The second-quarter results underscore the company’s growing commercial revenue base, fueled by the significant launch of its second commercial product, REZENOPY™, which has started to fulfill …
Solésence, Inc. announced second-quarter revenue of $15.3 million, a notable decrease from $20.4 million generated in the same quarter last year. This decline is partly attributed to the absence of a one-time revenue boost seen in Q2 2025, following a significant product launch and …
Splash Beverage Group, Inc. (NYSE American: SBEV) reported a substantial improvement in its financial performance, achieving a 64% reduction in its loss from continuing operations, which totaled around $4 million for the first half of 2026. This decrease is stark when compared to losses …
UroGen Pharma Ltd. (NASDAQ: URGN) has entered an Option and Research License Agreement with IntraGel Therapeutics, establishing a pathway for the development of advanced cancer treatments. This agreement provides UroGen with an exclusive option to secure worldwide licensing for IntraGel’s TumoCure, designed toLeverageSRGel delivery …
Merit Medical Systems Inc. (NASDAQ: MMSI) has made significant leadership changes as part of a reorganization of its global operations function. The company has eliminated the Chief Operating Officer position, resulting in Neil W. Peterson transitioning to a Senior Advisor role. Peterson will remain …
Potential Breakthrough in Skin Cancer Treatment
Clover Health Investments, Corp. (NASDAQ: CLOV) has released a supplemental Q&A addressingShareholderinquiries related to its second quarter 2026 performance. This Q&A is designed to foster transparency and facilitate continued engagement with its investor base. Among the significant takeaways is an insightful comparison of how …
Cosmos Health Inc. (NASDAQ: COSM) achieved a milestone by reporting record revenue of $19 million for the second quarter of 2026, marking a significant 28.8% increase compared to $14.75 million for the same period last year. This revenue growth stems from strong performance across …
Edesa Biotech, Inc. (NASDAQ: EDSA) has announced the issuance of 3,870,500 common shares at a price of $5.50 per share, which also includes common share warrants. This structured agreement is expected toYieldapproximately $23.1 million in net proceeds for the biotechnology firm. The funding will …
Please wait processing your request...